On May 14, BeiGene announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval to sonrotoclax, a BCL2 inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) mantle cell lymphoma (MCL) who have received at least two prior lines of systemic therapy, including a BTK inhibitor.
This approval carries two notable distinctions. It is the first new BCL2 inhibitor to receive FDA approval in a decade. It is also the only BCL2 inhibitor currently approved for an MCL indication in the United States. Before this approval, patients with MCL who progressed after BTK inhibitor therapy faced a significant gap in targeted treatment options. Sonrotoclax addresses that unmet need directly.
The approval also reflects BeiGene's expanding global regulatory footprint. The company now has three FDA-approved products: sonrotoclax, zanubrutinib (a BTK inhibitor), and tislelizumab (a PD-1 monoclonal antibody). This multi-product track record strengthens BeiGene's credibility for future global clinical development and regulatory submissions.